Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
PureTech Health PLC (ADR) - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
PRTC
Nasdaq
8731
https://puretechhealth.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for PureTech Health PLC (ADR)
PureTech Proposes $100 Million Capital Return
- Mar 19th, 2024 7:00 am
Bristol Myers Squibb Completes Acquisition of PureTech's Founded Entity Karuna Therapeutics for $14 Billion
- Mar 18th, 2024 1:52 pm
PureTech Receives Orphan Drug Designation for LYT-200 in Acute Myeloid Leukemia
- Mar 13th, 2024 11:00 am
PureTech to Present at Two Upcoming Investor Conferences
- Feb 27th, 2024 12:00 pm
PureTech Founded Entity Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx ® for Pediatric ADHD Patients in Japan
- Feb 27th, 2024 7:00 am
Down -8.13% in 4 Weeks, Here's Why PureTech Health PLC Sponsored ADR (PRTC) Looks Ripe for a Turnaround
- Feb 15th, 2024 2:35 pm
PureTech to Present at 42nd Annual J.P. Morgan Healthcare Conference
- Jan 3rd, 2024 12:00 pm
PureTech Founded Entity Karuna Therapeutics to be Acquired by Bristol Myers Squibb for $14 Billion
- Dec 22nd, 2023 2:13 pm
PureTech Year End Update and Outlook for 2024
- Dec 20th, 2023 7:00 am
PureTech Presents Data from Phase 1 Trial of LYT-200 Targeting Galectin-9 in Solid Tumors at the ESMO Immuno-Oncology Congress 2023
- Dec 7th, 2023 11:00 am
PureTech Founded Entity Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia
- Nov 29th, 2023 3:17 pm
PureTech Founded Entity Karuna Therapeutics Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia
- Nov 17th, 2023 7:00 am
PureTech's LYT-300 (Oral Allopregnanolone) Achieved Primary Endpoint in a Phase 2a Acute Anxiety Trial in Healthy Volunteers
- Nov 14th, 2023 7:00 am
PureTech Presents Data from LYT-100 (Deupirfenidone) Trial in Healthy Older Adults at CHEST Annual Meeting
- Oct 11th, 2023 11:00 am
PureTech Founded Entity Vedanta Biosciences Announces First Patient Dosed in Phase 2 Clinical Trial of VE202 for the Treatment of Ulcerative Colitis and Receives Fast Track Designation
- Oct 4th, 2023 11:05 am
KarXT, invented at PureTech, submitted for FDA Approval in Schizophrenia
- Sep 28th, 2023 11:38 am
PureTech Announces the Appointment of Robert Lyne as Chief Portfolio Officer
- Sep 27th, 2023 6:05 am
Half Year 2023 PureTech Health PLC Earnings Call
- Aug 30th, 2023 5:04 am
PureTech Health: Notice of Half-Yearly Results
- Aug 22nd, 2023 6:00 am
PureTech Awarded up to $11.4 Million from U.S. Department of Defense to Advance LYT-300 (Oral Allopregnanolone) for Fragile X-associated Tremor/Ataxia Syndrome
- Aug 1st, 2023 11:00 am
Scroll